List of Excipients in Branded Drug QUESTRAN

Generic Drugs Containing QUESTRAN

Company	Ingredient	NDC	Excipient
Endo USA Inc	cholestyramine	49884-936	ACACIA
Endo USA Inc	cholestyramine	49884-936	ANHYDROUS CITRIC ACID
Endo USA Inc	cholestyramine	49884-936	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in QUESTRAN?

# Of NDCs	Excipient
1	ACACIA
1	ANHYDROUS CITRIC ACID
1	D&C YELLOW NO. 10

Questran Excipient Strategy and Commercial Opportunities for Cholestyramine Products

Last updated: August 28, 2026

Questran is a legacy oral cholestyramine product whose commercial value depends more on formulation execution, palatability, dose convenience, and supply reliability than on active-ingredient exclusivity. The principal opportunities are sugar-free and low-sensory formulations, single-dose sachets, pediatric and bile-acid-diarrhea products, and generic products that improve dispersion without changing cholestyramine’s clinical function.

What is Questran and which excipients define its formulation?

Questran contains cholestyramine resin, a nonabsorbed bile-acid sequestrant supplied as a powder for oral suspension. The labeled dose is commonly expressed as one 4-gram packet or scoop. The product is mixed with liquid before administration and must not be taken as a dry powder.[1]

The Questran formulation uses excipients to solve four commercial problems:

1. Wetting and dispersion of an ion-exchange resin.
2. Taste and odor masking.
3. Color and product recognition.
4. Powder flow, dose uniformity, and consumer acceptability.

The FDA label identifies excipients in the Questran product family that include acacia, citric acid, colorants, flavor, polysorbate 80, and sucrose.[1] These materials create a flavored, sweetened powder that can be dispersed in water or another suitable beverage.

Formulation function	Questran excipient strategy	Commercial relevance
Suspending and dispersing agent	Acacia	Helps wet and disperse the resin in liquid
Acidity and flavor balance	Citric acid	Supports citrus flavor and reduces resin-associated sensory burden
Surfactant	Polysorbate 80	Improves wetting and dispersion
Sweetener and bulking agent	Sucrose	Improves palatability but limits diabetic and sugar-restricted use
Product identity	D&C Yellow No. 10 and FD&C Yellow No. 6	Supports visual differentiation
Taste masking	Orange or citrus flavor system	Important because cholestyramine is difficult to consume repeatedly

The resin itself is the dominant technical challenge. Cholestyramine does not dissolve like a conventional small-molecule oral solid. It forms a dispersion, and the user’s mixing technique affects dose delivery, mouthfeel, residue, and adherence.

What excipients create the main commercial risks for Questran?

The largest formulation risk is poor patient acceptance rather than chemical instability. Cholestyramine products can be gritty, thick, slow to disperse, and difficult to consume over long treatment periods.

Sucrose exposure

A sucrose-containing product can be commercially limited in patients with diabetes, metabolic syndrome, dental-risk concerns, or long-term use. A sugar-free product can target a broader population, but replacement sweeteners introduce their own risks:

• Aspartame may create labeling restrictions for patients with phenylketonuria.
• Sucralose can alter aftertaste and may require a different flavor system.
• Acesulfame potassium and high-intensity sweeteners can create bitterness.
• Sugar alcohols may cause gastrointestinal effects, which are undesirable in products used for bile-acid diarrhea.

A successful sugar-free Questran substitute must preserve palatability without increasing gastrointestinal complaints.

Flavor and odor masking

Citrus flavor is logical because acidity and orange notes can reduce the perception of resin taste. However, flavor systems must remain stable in a high-solid suspension and should not intensify bitterness after the product is mixed.

Potential development routes include:

• Orange-citrus systems with lower acid intensity.
• Fruit flavors designed for pediatric patients.
• Flavor-free products intended for mixing into yogurt, applesauce, or smoothies.
• Dual-flavor packaging that permits patient preference testing.

Flavor changes can create a meaningful commercial distinction even when the active ingredient and dose remain identical.

Dispersibility and sedimentation

The product should wet rapidly, disperse with minimal clumping, and remain drinkable for the time required to administer it. Excessive sedimentation can produce an inconsistent final dose if the patient does not consume the entire mixture.

Formulation variables include:

• Particle-size distribution of the resin.
• Acacia concentration.
• Surfactant level.
• Powder density and porosity.
• Mixing instructions.
• Liquid volume required for administration.
• Re-dispersibility after short standing times.

A product that disperses in 30 to 60 seconds with a smaller liquid volume could compete on convenience, particularly for older adults and patients with swallowing or fluid-restriction issues.

What Questran formulations are protected by patents?

Questran is based on an old, nonbiologic active ingredient and does not have remaining new chemical entity exclusivity. The original commercial and formulation patent position is legacy IP, not a current barrier comparable to an innovative branded medicine.

The practical IP landscape is:

IP category	Questran position	Commercial implication
Active ingredient	Cholestyramine is long established	No meaningful composition-of-matter barrier
Original formulation	Legacy protection is generally expired	Generic and reformulation entry is feasible
Method of use	Uses for hypercholesterolemia and cholestatic pruritus are established	Limited exclusivity value
Orange Book patents	Current risk must be assessed against the live FDA listing for the relevant NDA	Patent certification may still matter for an ANDA
Trademark	Questran and related branding may remain valuable	Brand confusion and trade-dress risk require clearance
Manufacturing know-how	Resin processing, particle size, flavoring, and powder handling can be proprietary	Trade secrets may create practical differentiation
New formulation patents	Available for novel delivery, sensory, or excipient systems	Strongest route for new commercial exclusivity

A new applicant should not rely on the old cholestyramine concept for patent protection. A defensible filing would need to claim a specific technical result, such as rapid wetting, improved suspension stability, reduced grit, improved taste, reduced liquid volume, or a defined sugar-free excipient system.

Patent claims directed only to “cholestyramine plus a flavor” would face substantial obviousness risk. Stronger claim structures would combine:

• Defined resin particle-size limits.
• Specified wetting-agent and suspending-agent ranges.
• A measurable dispersion time.
• A sedimentation or redispersibility endpoint.
• A sensory threshold.
• A defined moisture or water-activity range.
• A unit-dose package that preserves powder flow and stability.

When does Questran lose exclusivity?

Questran has already lost the principal exclusivity associated with a new chemical product. It is a legacy prescription product, and commercial entry is primarily governed by FDA approval requirements, patent certifications, manufacturing capability, and market access.

FDA regulatory status

Cholestyramine powder for oral suspension is regulated as a prescription drug. The relevant regulatory pathway for a therapeutically equivalent generic is generally an abbreviated new drug application, subject to FDA requirements for pharmaceutical equivalence, labeling, quality, and bioequivalence considerations applicable to a nonabsorbed resin product.[2]

Because cholestyramine acts locally in the gastrointestinal tract and is not systemically absorbed in the conventional sense, conventional plasma pharmacokinetic bioequivalence may not fully describe product performance. The key technical issues include:

• Resin identity and exchange capacity.
• Particle-size distribution.
• Dose uniformity.
• Dispersion characteristics.
• Impurity controls.
• In vitro performance.
• Comparative product quality.

The FDA’s product-specific guidance and current Orange Book entries control the regulatory strategy for a proposed ANDA.[2,3]

Orange Book status

The Orange Book remains the controlling source for listed drug patents, therapeutic-equivalence evaluations, and reference-product information.[3] Questran’s commercial assessment should distinguish between:

• The reference listed drug.
• Questran Light or other branded variants.
• Generic cholestyramine products.
• Different strengths, packet sizes, and labeling configurations.

An ANDA sponsor must review the live Orange Book listing for the selected reference product and submit the appropriate patent certification. A Paragraph IV certification may trigger patent litigation and a potential 30-month stay if the statutory conditions are met.[4]

Because Questran is an old product, the central risk is unlikely to be NCE patent litigation. The more relevant risk is an unexpected listed formulation or method-of-use patent, a regulatory determination that the proposed product does not adequately match the reference, or a manufacturing-quality deficiency.

Which companies are challenging Questran through generic competition?

Generic cholestyramine products have historically competed with Questran and Questran Light. The relevant competitive set includes products marketed under the cholestyramine name by multiple generic and specialty pharmaceutical companies, subject to changes in supply and labeling.

Competition is based on:

• Price per 4-gram dose.
• Availability of packets versus multidose cans.
• Sugar-containing versus sugar-free formulation.
• Flavor and patient acceptance.
• Pharmacy wholesaler access.
• Medicaid and managed-care contracting.
• Manufacturing continuity.

The product is vulnerable to supply shortages because resin processing, powder handling, flavoring, and packaging are more specialized than those of a standard tablet. A reliable second-source supplier can obtain a commercial advantage even without superior patent protection.

What are the best excipient opportunities for a Questran competitor?

1. Sugar-free and low-calorie cholestyramine

A sugar-free formulation is the clearest broad-market opportunity. It can target chronic users who need to avoid sucrose and patients taking the product for bile-acid diarrhea rather than lipid management.

The formulation must avoid trading sucrose-related concerns for:

• Excessive sweetness.
• Bitter aftertaste.
• Gastrointestinal intolerance.
• Phenylalanine labeling requirements.
• Poor powder flow.
• Reduced suspension quality.

A low-sugar product with a neutral or lightly citrus profile could occupy a position between conventional Questran and strongly sweetened “light” products.

2. Rapid-dispersing powder

A rapid-dispersing formulation could reduce clumping and shorten the time from opening the packet to administration. The opportunity is strongest if the product can be mixed in a smaller volume of liquid while maintaining acceptable mouthfeel.

Relevant development endpoints include:

• Time to complete wetting.
• Number of stirs required.
• Maximum clump size.
• Sedimentation after five minutes.
• Residual resin on the container.
• Percentage of labeled dose recovered from the prepared mixture.

These endpoints can support both product claims and formulation patent claims if they are tied to a novel excipient and particle-size system.

3. Single-dose stick packs

A stick pack or narrow sachet can improve portability and reduce dose measurement errors. It also allows the sponsor to control moisture exposure more effectively than a large multidose container.

Commercial benefits include:

• Better adherence during travel.
• Improved pharmacy dispensing.
• Unit-dose reimbursement.
• Easier use in long-term-care facilities.
• Lower risk of repeated container opening.

Packaging claims may be protectable through configuration, moisture-barrier design, or combination with a defined powder formulation, although packaging patents should not be treated as a substitute for formulation protection.

4. Pediatric and caregiver-oriented products

Cholestyramine is used in pediatric settings under physician supervision for selected indications. A lower-sensory formulation, easier mixing instructions, and a smaller unit dose could improve caregiver administration.

The commercial opportunity depends on avoiding excessive sweetness, coloring, and flavor intensity. A product designed to mix into a small amount of approved soft food may be more useful than a product optimized only for water.

5. Product for bile-acid diarrhea

Bile-acid diarrhea creates a commercially distinct use case from cholesterol reduction. These patients may use cholestyramine chronically and are more sensitive to taste, constipation, bloating, and daily administration burden.

A reformulation targeting this segment could emphasize:

• Better taste.
• Lower residue.
• Smaller preparation volume.
• Flexible packet strengths.
• More neutral flavor.
• Packaging compatible with recurring monthly use.

The product cannot claim a new indication without appropriate regulatory support, but commercial segmentation can target physician and patient needs within approved labeling and lawful promotional limits.

How strong is the patent estate for a new Questran excipient formulation?

A new cholestyramine product can have a moderate formulation patent position if the sponsor generates comparative data and claims a technically defined composition. The patent estate is weak if it relies only on conventional flavors, sweeteners, or standard suspending agents.

Stronger patent opportunities

• Specific excipient ratios linked to rapid dispersion.
• Particle-size and viscosity combinations.
• Low-sugar systems with demonstrated sensory performance.
• Moisture-controlled powders with improved stability.
• Formulations that reduce container residue.
• Defined unit-dose packaging and powder-flow characteristics.
• Combination products with a technically justified co-administered nutrient or medication, subject to regulatory and interaction constraints.

Weaker patent opportunities

• Orange flavor alone.
• Sucrose replacement without performance data.
• Acacia or polysorbate 80 at routine concentrations.
• Conventional packet packaging.
• Broad claims covering any cholestyramine powder with a sweetener.

A sponsor should build the patent program around measurable performance data generated before public disclosure. The most valuable protection would combine composition claims, process claims, and method-of-use claims directed to administration convenience.

What manufacturing and IP barriers affect Questran entry?

The main barriers are technical and operational.

Resin quality

Cholestyramine resin must meet identity, purity, exchange-capacity, particle-size, and microbiological requirements. Variation in resin characteristics can change mouthfeel and dispersion even when the labeled dose is unchanged.

Powder processing

The formulation must maintain uniform distribution of low-dose excipients such as flavors, colorants, and surfactants. Segregation during blending or filling can create variability between packets.

Moisture control

Moisture can affect flow, clumping, flavor stability, and packet fill weight. High-barrier foil laminates and controlled packaging operations may be necessary.

Supply-chain concentration

A sponsor dependent on one resin supplier faces a material continuity risk. Dual sourcing can improve resilience but may require comparability work because resin particle size and functional performance can differ between suppliers.

Trade secrets

The most durable practical differentiation may reside in:

• Resin conditioning.
• Blending sequence.
• Flavor incorporation.
• Granulation or agglomeration parameters.
• Moisture-control specifications.
• Filling and sealing conditions.

These processes can remain valuable even where patent protection is limited.

How does Questran compare with other bile-acid sequestrants?

Product	Active ingredient	Dosage form	Main formulation issue	Competitive position
Questran	Cholestyramine	Powder for oral suspension	Taste, grit, dispersion, sucrose	Established but administration-burdened
Questran Light	Cholestyramine	Powder for oral suspension	Sweetener and flavor acceptance	Sugar-reduction positioning
Colestid	Colestipol	Granules or tablets	Bulk, swallowing, gastrointestinal tolerance	Alternative bile-acid sequestrant
Welchol	Colesevelam	Tablets or suspension	Tablet burden and cost	More convenient solid oral option, usually higher cost

Cholestyramine has a cost and clinical familiarity advantage. Colesevelam has a convenience advantage because it is available in solid oral dosage forms, while colestipol competes through alternative granule and tablet presentations.[5,6]

The commercial case for an improved Questran product is strongest where the sponsor can reduce the administration burden without losing the cost advantage of cholestyramine.

What generic launch scenarios exist for Questran?

Price-led launch

A conventional generic powder can enter with limited differentiation and compete through contract pricing, wholesaler availability, and pharmacy substitution. This strategy has low IP value and exposes the product to rapid price erosion.

Quality-led launch

A sponsor can position a product around improved dispersibility, better flavor, sugar-free composition, or more reliable unit-dose packaging. This may support a premium within cash-pay, specialty, long-term-care, or direct-to-consumer channels, although prescription substitution rules limit brand messaging.

Dual-product launch

A company can launch a standard low-cost generic and a differentiated formulation under separate labels. The generic captures formulary volume, while the differentiated product targets chronic users and specialty prescribers.

Supply-security launch

A manufacturer with dependable resin supply and domestic or diversified packaging can win contracts during competitor shortages. This strategy depends on validated capacity, quality systems, and reliable serialization and distribution.

What revenue exposure and licensing opportunities exist?

Questran is unlikely to represent a major high-growth branded asset. Its value is more likely to arise from recurring chronic use, generic volume, manufacturing scale, and portfolio fit.

Potential licensing structures include:

• Licensing a sugar-free formulation to a generic manufacturer.
• Supplying a differentiated cholestyramine powder under a private-label agreement.
• Out-licensing a rapid-dispersion technology across oral suspensions.
• Co-developing a pediatric or long-term-care presentation.
• Licensing resin-processing know-how to an established ANDA holder.
• Entering a regional commercialization agreement where local pharmacy access is stronger.

The most credible licensee is a company that already has FDA-approved oral powders, specialty pharmacy relationships, or bile-acid sequestrant distribution. A technology owner without manufacturing and regulatory infrastructure may have difficulty monetizing a formulation-only asset.

What patent litigation and Paragraph IV risks affect Questran?

Questran’s litigation risk is structurally lower than that of a recently approved branded drug because its primary exclusivity periods have expired. The relevant issues remain:

• Whether the selected reference product has live Orange Book-listed patents.
• Whether a proposed generic uses a different formulation that requires additional clinical or in vitro support.
• Whether a new branded reformulation creates enforceable patent claims.
• Whether method-of-use patents are carved out through labeling.
• Whether trademark or trade-dress disputes arise from packaging and color.

A Paragraph IV filing against a listed patent can lead to litigation and a statutory stay of approval under the Hatch-Waxman framework.[4] For a new excipient formulation, the sponsor should expect freedom-to-operate review across FDA-listed patents, published applications, expired patents, and competitor trade secrets.

Key Takeaways

• Questran is a legacy cholestyramine powder with no meaningful new chemical entity exclusivity remaining.
• The core commercial problem is patient acceptance: taste, grit, clumping, sedimentation, and preparation burden.
• The highest-value excipient opportunity is a sugar-free, low-sensory formulation with rapid wetting and low residue.
• Acacia, citric acid, polysorbate 80, sweeteners, colors, and flavor systems materially affect product performance.
• A new formulation patent should claim defined excipient ratios and measurable dispersion or sensory outcomes.
• Single-dose stick packs and smaller-volume preparation can support differentiated positioning.
• Biosimilar risk is not applicable because Questran is a nonbiologic small-molecule resin product.
• Generic entry risk is high for conventional cholestyramine powder, while differentiated formulation entry can create moderate commercial and IP protection.
• The strongest practical barriers are resin sourcing, powder processing, moisture control, dose uniformity, and manufacturing know-how.
• The Orange Book and current FDA product-specific requirements determine the live Paragraph IV and ANDA risk for any proposed entrant.

FAQs About Questran Excipient Strategy

Can Questran be reformulated without changing the active ingredient?

Yes. A sponsor can change flavor, sweetener, suspending agent, surfactant, particle-size distribution, packaging, and other excipients, provided the product remains compliant with FDA requirements and performs appropriately against the reference product.

Is a sugar-free cholestyramine product commercially attractive?

Yes. Sugar-free cholestyramine can target patients with diabetes, metabolic disease, dental concerns, and long-term treatment needs. The formulation must avoid excessive sweetness and gastrointestinal effects from the replacement sweetener.

Can a new Questran product receive formulation patent protection?

Yes, if the formulation is novel and non-obvious and demonstrates a defined technical benefit. Claims based only on routine flavoring or substitution of one conventional sweetener for another are comparatively weak.

Does cholestyramine require a biosimilar pathway?

No. Cholestyramine is a nonbiologic resin. A follow-on product generally follows the applicable generic-drug pathway rather than the biosimilar pathway.

What is the most defensible commercial positioning for a new cholestyramine product?

The strongest positioning combines sugar-free composition, improved flavor, rapid dispersion, unit-dose packaging, and dependable supply. Price alone is easier for competitors to match than a validated formulation and packaging platform.

References

1. U.S. Food and Drug Administration. (n.d.). Questran (cholestyramine for oral suspension) prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.

5. U.S. Food and Drug Administration. (n.d.). Welchol (colesevelam hydrochloride) prescribing information. DailyMed.

6. U.S. Food and Drug Administration. (n.d.). Colestid (colestipol hydrochloride) prescribing information. DailyMed.